Thoracic and Gastrointestinal Oncology Branch

Co-Chiefs
Raffit Hassan, M.D.
David S. Schrump, M.D.

The Thoracic and Gastrointestinal (GI) Oncology Branch (TGIB) was established in October 2013, following re-organization of clinical branches within the Center for Cancer Research at NCI. The impetus for formation of this Branch was to integrate and synergize multidisciplinary research and clinical activities pertaining to aerodigestive tract malignancies, and hasten the development of novel treatments for these neoplasms. The TGIB is a large branch that spans the spectrum of basic research, clinical trials and patient care.

Research Interests of TGIB Members

David S. Schrump, M.D., is a thoracic surgeon who is internationally recognized for surgical expertise pertaining to lung and esophageal cancers, malignant pleural mesothelioma, chest wall sarcomas and pulmonary metastases. His research efforts are focused on the elucidation of epigenetic mechanisms of gene regulation in lung and esophageal cancers and malignant pleural mesothelioma, and the development of epigenetic regimens including chromatin remodeling agents and novel tumor vaccines for the treatment of these neoplasms.

Raffit Hassan, M.D., is a medical oncologist who heads the medical thoracic oncology program. His laboratory and clinical work is focused on targeting the tumor differentiation antigen mesothelin for the treatment of malignant mesothelioma and other solid tumors.

Tim F. Greten, M.D., is a medical oncologist whose research efforts focus on restoring anti-tumor immunity by elimination of immune suppressor functions of myeloid-derived suppressor cells, as well as activation of existing tumor-specific T cell responses in the tumor microenvironment of liver tumors and other GI cancers.

Udayan Guha, M.D., PhD., is a medical oncologist who is utilizing proteo-genomic approaches to evaluate signaling pathways altered during pulmonary carcinogenesis, with a focus on mutant epidermal growth factor receptor (EGFR)-driven lung adenocarcinoma.

Chuong Dinh Hoang, M.D. is a thoracic surgeon whose research focus is in thoracic surgical oncology, with emphasis on maligant mesothelioma and thymic neoplasms. His clinical expertise includes lung cancer, other primary lung tumors, mesothelioma, thymic malignancies, esophageal cancer, pulmonary metastases, Pancoast tumors, and tracheal cancers.

R. Taylor Ripley, M.D., is a thoracic surgeon who is developing a laboratory effort in the metabolomic profiles of esophageal cancer.  His clinical expertise includes lung cancer, mesothelioma, thymic malignancies, pulmonary metastasis, and minimally-invasive thoracic surgery.

Udo Rudloff M.D., Ph.D., is a surgical oncologist with expertise in hepatobiliary malignancies whose laboratory efforts focus on drug development for pancreas cancer using innovative in vitro and in vivo preclinical methods including high-throughput screening and RNAi techniques to characterize mechanisms of resistance to small molecule inhibitors targeting MAPK and PI3K-Akt pathways.

Jeremy L. Davis, M.D., is a surgical oncologist whose research focus is in upper gastrointestinal tract malignancy.  His areas of expertise include gastric cancer, including GE junction tumors, and hepato-biliary and pancreatic cancer, including primary and metastatic tumors of the liver.

Austin G. Duffy, M.D., is a medical oncologist who serves as principal investigator or lead associate investigator on several early phase clinical trials in hepatic, pancreatic and colorectal cancers; his translational and laboratory interests relate to immune suppressor mechanisms in human cancer.

Marybeth S. Hughes, M.D., F.A.C.S., is a surgical oncologist who, along with Dr. Rudloff, provides general surgical consultative services for all patients on NIH protocols. Dr. Hughes oversees the NCI Surgical Oncology Fellowship Program. Her research efforts focus on regional therapies for intra-abdominal malignancies including the use of percutaneous hepatic perfusion, as well as cytoreductive surgery and HIPEC (hyperthermic intraperitonel extracorporeal chemotherapy) for adrenocortical cancers and peritoneal mesothelioma.

Arun Rajan, M.D., is a medical oncologist whose research interests focus on developing new therapies for thoracic malignancies, especially thymic cancers; he is currently evaluating the insulin-like growth factor-1 receptor (IGF-1R) inhibitor, cixutumumab and the multikinase inhibitor sunitinib in thymomas and thymic cancers.

Anish Thomas, MBBS, M.D.,  is a medical oncologist whose clinical focus is on evaluation of novel targeted therapies for thoracic malignancies. His translational interests include understanding the evolution of chemotherapy resistance and the use of synthetic lethal approaches involving the DNA damage response pathways in small cell lung cancer.

 

 

 

 

 

Position Contact Name Contact E-mail Contact Phone Research Area Keywords Number of Positions
Postdoctoral Fellow Dr. Tim Greten

tim.greten@nih.gov

301-451-4723

tumor immunology, microbiome, liver, cancer, myeloid cells

1

About

The Thoracic and Gastrointestinal (GI) Oncology Branch (TGIB) was established in October 2013, following re-organization of clinical branches within the Center for Cancer Research at NCI. The impetus for formation of this Branch was to integrate and synergize multidisciplinary research and clinical activities pertaining to aerodigestive tract malignancies, and hasten the development of novel treatments for these neoplasms. The TGIB is a large branch that spans the spectrum of basic research, clinical trials and patient care.

Research Interests of TGIB Members

David S. Schrump, M.D., is a thoracic surgeon who is internationally recognized for surgical expertise pertaining to lung and esophageal cancers, malignant pleural mesothelioma, chest wall sarcomas and pulmonary metastases. His research efforts are focused on the elucidation of epigenetic mechanisms of gene regulation in lung and esophageal cancers and malignant pleural mesothelioma, and the development of epigenetic regimens including chromatin remodeling agents and novel tumor vaccines for the treatment of these neoplasms.

Raffit Hassan, M.D., is a medical oncologist who heads the medical thoracic oncology program. His laboratory and clinical work is focused on targeting the tumor differentiation antigen mesothelin for the treatment of malignant mesothelioma and other solid tumors.

Tim F. Greten, M.D., is a medical oncologist whose research efforts focus on restoring anti-tumor immunity by elimination of immune suppressor functions of myeloid-derived suppressor cells, as well as activation of existing tumor-specific T cell responses in the tumor microenvironment of liver tumors and other GI cancers.

Udayan Guha, M.D., PhD., is a medical oncologist who is utilizing proteo-genomic approaches to evaluate signaling pathways altered during pulmonary carcinogenesis, with a focus on mutant epidermal growth factor receptor (EGFR)-driven lung adenocarcinoma.

Chuong Dinh Hoang, M.D. is a thoracic surgeon whose research focus is in thoracic surgical oncology, with emphasis on maligant mesothelioma and thymic neoplasms. His clinical expertise includes lung cancer, other primary lung tumors, mesothelioma, thymic malignancies, esophageal cancer, pulmonary metastases, Pancoast tumors, and tracheal cancers.

R. Taylor Ripley, M.D., is a thoracic surgeon who is developing a laboratory effort in the metabolomic profiles of esophageal cancer.  His clinical expertise includes lung cancer, mesothelioma, thymic malignancies, pulmonary metastasis, and minimally-invasive thoracic surgery.

Udo Rudloff M.D., Ph.D., is a surgical oncologist with expertise in hepatobiliary malignancies whose laboratory efforts focus on drug development for pancreas cancer using innovative in vitro and in vivo preclinical methods including high-throughput screening and RNAi techniques to characterize mechanisms of resistance to small molecule inhibitors targeting MAPK and PI3K-Akt pathways.

Jeremy L. Davis, M.D., is a surgical oncologist whose research focus is in upper gastrointestinal tract malignancy.  His areas of expertise include gastric cancer, including GE junction tumors, and hepato-biliary and pancreatic cancer, including primary and metastatic tumors of the liver.

Austin G. Duffy, M.D., is a medical oncologist who serves as principal investigator or lead associate investigator on several early phase clinical trials in hepatic, pancreatic and colorectal cancers; his translational and laboratory interests relate to immune suppressor mechanisms in human cancer.

Marybeth S. Hughes, M.D., F.A.C.S., is a surgical oncologist who, along with Dr. Rudloff, provides general surgical consultative services for all patients on NIH protocols. Dr. Hughes oversees the NCI Surgical Oncology Fellowship Program. Her research efforts focus on regional therapies for intra-abdominal malignancies including the use of percutaneous hepatic perfusion, as well as cytoreductive surgery and HIPEC (hyperthermic intraperitonel extracorporeal chemotherapy) for adrenocortical cancers and peritoneal mesothelioma.

Arun Rajan, M.D., is a medical oncologist whose research interests focus on developing new therapies for thoracic malignancies, especially thymic cancers; he is currently evaluating the insulin-like growth factor-1 receptor (IGF-1R) inhibitor, cixutumumab and the multikinase inhibitor sunitinib in thymomas and thymic cancers.

Anish Thomas, MBBS, M.D.,  is a medical oncologist whose clinical focus is on evaluation of novel targeted therapies for thoracic malignancies. His translational interests include understanding the evolution of chemotherapy resistance and the use of synthetic lethal approaches involving the DNA damage response pathways in small cell lung cancer.

 

 

 

 

 

Clinical Trials

PI & Key Staff

Positions

Position Contact Name Contact E-mail Contact Phone Research Area Keywords Number of Positions
Postdoctoral Fellow Dr. Tim Greten

tim.greten@nih.gov

301-451-4723

tumor immunology, microbiome, liver, cancer, myeloid cells

1

Contact Info

Thoracic and Gastrointestinal Oncology Branch
Center for Cancer Research
National Cancer Institute
Building 10, Room 4-3942
Bethesda, MD 20892-1201
Ph: 301-496-2128
Secretary
301-496-2127
Secretary
301-594-0911